Women's representation in clinical trials of patients with chronic kidney disease
Clinical Kidney Journal · 31.08.2023 · 16 (9) · 1457-1464
DOI: 10.1093/ckj/sfad018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 02.02.2023. Verfasst von Ana-Catarina Pinho-Gomes und 3 weiteren Autor:innen. Beteiligte Einrichtung: The George Institute for Global Health, Imperial College London, UK. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Heart Foundation of Australia, Medical Research Council.
Abstract (Originalsprache)
Background
Sex and gender differences in chronic kidney disease (CKD), including epidemiology and response to treatment, remain poorly understood. This study aimed to investigate how women are represented in CKD clinical trials and whether sex- and gender-disaggregated outcomes were reported.
Methods
Clinical trials on CKD were identified from ClinicalTrials.gov. Randomised, phase 3/4 trials with ≥100 participants were selected to quantify women's representation among participants by computing the participation:prevalence ratio (PPR) and investigating whether sex-disaggregated analyses had been performed.
Results
In total, 192 CKD trials registered on ClinicalTrials.gov and published between 1995 and 2022 were included. Overall, women accounted for 66 875 (45%) of the 147 136 participants. Women's participation in clinical trials was lower than their representation in the underlying CKD population globally (55%). The PPR was 0.75 (95% confidence interval 0.72–0.78), with no significant variation irrespective of mean age, CKD stage, dialysis, location, type of intervention or funding agency. A total of 39 (20%) trials reported sex-disaggregated efficacy outcomes and none reported sex-disaggregated safety outcomes.
Conclusion
Women's participation in CKD clinical trials was lower than their representation in the underlying CKD population. Sex-disaggregated efficacy and safety outcomes were rarely reported. Improving women's enrolment into clinical trials is crucial to enable sex- and gender-disaggregated analysis and thus identify potential differences in treatment response between women and men.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The George Institute for Global Health, Imperial College London, UK.
- Institute of Health Informatics, University College London, London, UK.
- The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
- Sydney School of Public Health, Sydney Medical School, University of Sydney, New South Wales, Australia.
ORCID-Profile: Ana-Catarina Pinho-Gomes
Förderung
- National Heart Foundation of Australia
- Medical Research Council
Zitieren
APA
Pinho-Gomes, A. C., Carcel, C., Woodward, M., & Hockham, C. (2023). Women's representation in clinical trials of patients with chronic kidney disease. Clinical Kidney Journal, 16(9), 1457-1464. https://doi.org/10.1093/ckj/sfad018
Vancouver
Pinho-Gomes AC, Carcel C, Woodward M, Hockham C. Women's representation in clinical trials of patients with chronic kidney disease. Clinical Kidney Journal. 2023;16(9):1457-1464. doi:10.1093/ckj/sfad018
BibTeX
@article{PinhoGomes2023,
author = {Pinho-Gomes, Ana-Catarina and Carcel, Cheryl and Woodward, Mark and Hockham, Carinna},
title = {Women's representation in clinical trials of patients with chronic kidney disease},
journal = {Clinical Kidney Journal},
year = {2023},
volume = {16},
number = {9},
pages = {1457--1464},
doi = {10.1093/ckj/sfad018}
}
EUVIMED